| P2093 | author name string | T Wong | |
| | S Parry | |
| | L Crossman | |
| | P J Morley | |
| | I J Owens | |
| | R J Fenton | |
| | D Gower | |
| P2860 | cites work | Influenza vaccines. A reappraisal of their use. | Q41676828 |
| | Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus | Q43209132 |
| | Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers | Q44779710 |
| | Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. | Q45114160 |
| | A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection | Q45148150 |
| | Amantadine resistance in clinical influenza A (H3N2) and (H1N1) virus isolates | Q45829317 |
| | Evaluation of amantadine in artificially induced A2 and B influenza | Q47770553 |
| | Field investigation of influenza vaccine effectiveness on morbidity. | Q50873540 |
| | The Roles of Vaccination and Amantadine Prophylaxis in Controlling an Outbreak of Influenza A (H3N2) in a Nursing Home | Q57112977 |
| | Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A | Q69595599 |
| | Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group | Q77719323 |
| | Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice | Q28367135 |
| | Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) | Q28368367 |
| | 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro | Q28378588 |
| | Rational design of potent sialidase-based inhibitors of influenza virus replication | Q29616647 |
| | Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice | Q30431958 |
| | Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics | Q30451349 |
| | Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections | Q30462342 |
| | Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza | Q30467966 |
| | Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. | Q30471016 |
| | GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets | Q35120465 |
| | Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus | Q35542114 |
| | Implications of viral resistance to amantadine in control of influenza A | Q35811011 |
| | Immunity to influenza in ferrets. I. Response to live and killed virus | Q36130219 |
| | Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection | Q36866575 |
| | Prophylaxis and treatment of influenza | Q38139920 |
| | Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. | Q39557208 |
| | Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial | Q40636281 |
| | Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor | Q41042625 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | influenza A virus | Q834390 |
| | zanamivir | Q146075 |
| P304 | page(s) | 2642-2647 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract | |
| P478 | volume | 43 | |